Article Details
Retrieved on: 2024-07-24 18:51:31
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Organigram Holdings Inc.'s investment in Phylos Bioscience Inc. to diversify its cannabis product offerings, particularly in high THCV cultivars, amidst the evolving drug policy and cannabis legalization landscape in the U.S. This reflects broader trends in cannabis regulation and market dynamics, emphasizing Organigram's strategic positioning in both medical and recreational cannabis markets globally.
Article found on: www.investing.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here